Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPTN 046: Extended Nevirapine for HIV Prevention
NCT00074412Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2007
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Extended NVP with Placebo (2 arms). Primary endpoints: HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks and Frequency and Severity of Adverse Reactions at 18 months. Started Jan 2007; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00074412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074412.